Clinical Trial Update: A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating OL-108 in relapsed/refractory autoimmune diseases is currently recruiting, including systemic lupus erythematosus, idiopathic inflamm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myopathy
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• OL-108

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM) | Phase 1 | Status: RECRUITING